These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12926806)

  • 1. Treatment of occupational koilonychia with tazarotene gel.
    Hagman JH; Ginebri A; Mordenti C; De Simoni I; Chimenti S
    Acta Derm Venereol; 2003; 83(4):296-7. PubMed ID: 12926806
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of Favre-Racouchot disease with 0.05% tazarotene gel.
    Rallis E; Karanikola E; Verros C
    Arch Dermatol; 2007 Jun; 143(6):810-2. PubMed ID: 17576962
    [No Abstract]   [Full Text] [Related]  

  • 3. Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
    Piraccini BM; Venturi M; Patrizi A
    G Ital Dermatol Venereol; 2014 Jun; 149(3):363-6. PubMed ID: 24819765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study.
    Bianchi L; Soda R; Diluvio L; Chimenti S
    Br J Dermatol; 2003 Jul; 149(1):207-9. PubMed ID: 12890227
    [No Abstract]   [Full Text] [Related]  

  • 5. Dermoscopic monitoring of tazarotene treatment of superficial basal cell carcinoma.
    Peris K; Ferrari A; Fargnoli MC; Piccolo D; Chimenti S
    Dermatol Surg; 2005 Feb; 31(2):217-20. PubMed ID: 15762218
    [No Abstract]   [Full Text] [Related]  

  • 6. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.
    Diluvio L; Campione E; Paternò EJ; Mordenti C; El Hachem M; Chimenti S
    Pediatr Dermatol; 2007; 24(3):332-3. PubMed ID: 17542899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occupational trachyonychia due to psoriasis: report of a case successfully treated with oral acitretin.
    Tosti A; Bellavista S; Iorizzo M; Vincenzi C
    Contact Dermatitis; 2006 Feb; 54(2):123-4. PubMed ID: 16487289
    [No Abstract]   [Full Text] [Related]  

  • 8. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
    Scher RK; Stiller M; Zhu YI
    Cutis; 2001 Nov; 68(5):355-8. PubMed ID: 11766122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elephantiasis nostrum verrucosa of the abdomen: clinical results with tazarotene.
    Boyd J; Sloan S; Meffert J
    J Drugs Dermatol; 2004; 3(4):446-8. PubMed ID: 15303792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
    Rigopoulos D; Gregoriou S; Katsambas A
    Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
    Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete regression of keratoacanthoma with topical tazarotene gel 0.1%: therapeutic and pathophysiological perspectives.
    Paolino G; Muscardin LM; Donati M; Didona D; Panetta C; Donati P
    G Ital Dermatol Venereol; 2019 Apr; 154(2):220-221. PubMed ID: 28895378
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
    Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
    Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A status report on topical tazarotene in the management of acne vulgaris.
    Del Rosso JQ; Tanghetti E
    J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment.
    Fischer-Levancini C; Sánchez-Regaña M; Llambí F; Collgros H; Expósito-Serrano V; Umbert-Millet P
    Actas Dermosifiliogr; 2012 Oct; 103(8):725-8. PubMed ID: 22818395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tazarotene foam, 0.1%, for the treatment of acne.
    Smith JA; Narahari S; Hill D; Feldman SR
    Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene.
    Cotellessa C; Cuevas-Covarrubias SA; Valeri P; Fargnoli MC; Peris K
    Acta Derm Venereol; 2005; 85(4):346-8. PubMed ID: 16191859
    [No Abstract]   [Full Text] [Related]  

  • 20. [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
    Henno A; Hua MT; de la Brassinne M
    Rev Med Liege; 2003 Nov; 58(11):706-8. PubMed ID: 14748200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.